MedChemNet and Infectious Diseases Hub recently attended the first two days of the 19th RSC / SCI Medicinal Chemistry Symposium. Here, you can catch up on the session delving into drug discovery for the neglected tropical diseases.
Browsing: Basic > Pre-clinical Trials
Researchers have discovered that antibodies taken from dengue virus infected individuals are effective in treating Zika infection – a closely related flavivirus – in rodents.
A novel trispecific antibody has been developed by researchers from the NIH and Sanofi, demonstrating effectiveness against of 99% of HIV strains and protective immunity in non-human primates.
Research in mice and cell lines has demonstrated the potential of Zika virus to target and kill glioblastoma stem cells, suggesting a possible new treatment for this brain cancer.
Improved therapeutic strategies are in urgent need for better control and eradication of tuberculosis. In this editorial, the authors evaluate interleukin-37 as a new molecular target for the therapy of tuberculosis.
Researchers have demonstrated an imaging technique utilizing PET, which allows non-invasive and real-time monitoring of dengue infection in mouse models.
Research presented at ASM Microbe has reported a Zika vaccine based on the NS1 protein can induce protective immunity in mouse models after a single dose.
A team from the Scripps Research Institute have determined the structure of clade C HIV-1 envelope glycoprotein, an immunogen that could be utilized in a future HIV vaccine.
Development of protein vaccine to prevent congenital infection is a public health priority, this research investigates the design of a mucosal synthetic pathogen as a vaccine strategy against congenital toxoplasmosis.